Von Willebrand Disease Epidemiology Forecast Report 2030 | Von Willebrand Disease Epidemiology Analysis 2030 | DelveInsight

(MENAFN- GetNews) DelveInsight’s ‘Von Willebrand Disease – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Von Willebrand Disease Epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight launched a new report on Von Willebrand Disease Epidemiology Forecast, 2030.

Von Willebrand disease is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms. 

DelveInsight's ' Von Willebrand Disease Epidemiology Forecast to 2030 ' report delivers an in-depth understanding of the disease, historical and forecasted Von Willebrand Disease Epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key highlights from the Von Willebrand Disease Epidemiology Report:

As per the study, the prevalence of Von Willebrand Disease among Saudi adolescents in the selected student population was 1.5%. The prevalence of type 1 Von Willebrand Disease was reported as 1.04%.

According to the article, Von Willebrand Disease is the most common inherited bleeding disorder, with an estimated prevalence of 1% of the population.

A study shows a higher prevalence (2.7%) of Von Willebrand Disease among women. The study also showed a slightly higher prevalence of rare Von Willebrand Disease type 3 (about 12.5% of the diagnosed cases) compared to 5–10% in the literature.

Visit for more @ Von Willebrand Disease Epidemiology Insights

Scope of the Von Willebrand Disease Epidemiology report:

The Von Willebrand Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns

The Von Willebrand Disease Epidemiology Report and Model provide an overview of the risk factors and global trends of Von Willebrand Disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of Von Willebrand Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The report helps to recognize the growth opportunities in the 7MM concerning the patient population

The report assesses the disease risk and burden and highlights the unmet needs of Von Willebrand Disease

The report provides the segmentation of the Von Willebrand Disease epidemiology

Table of Contents:

1. Key Insights

2. Executive Summary of Von Willebrand Disease

3. Von Willebrand Disease Epidemiology Overview at a Glance

4. Von Willebrand Disease: Disease Background and Overview

5. Epidemiology and Patient Population

6. Case Reports

7. Country Wise-Epidemiology of Von Willebrand Disease 

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Related Reports:

Von Willebrand Disease Market

DelveInsight's 'Von Willebrand Disease-Market Insights, Epidemiology, and Market Forecast—2030' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Von Willebrand Disease Pipeline 

“Von Willebrand Disease Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Von Willebrand Disease market. A detailed picture of the Von Willebrand Disease pipeline landscape is provided, which includes the disease overview and Von Willebrand Disease treatment guidelines.

MENAFN08092021003238003268ID1102760957